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Abstract
Although Attention-Deficit/Hyperactivity Disorder shows (ADHD) male predominance, females 
are significantly impaired and exhibit additional comorbid disorders during adolescence. However, 
no empirical work has examined the influence of cyclical fluctuating steroids on ADHD symptoms 
in women. The present study examined estradiol (E2), progesterone (P4), and testosterone (T) 
associations with ADHD symptoms across the menstrual cycle in regularly-cycling young women 
(N=32), examining trait impulsivity as a moderator. Women completed a baseline measure of trait 
impulsivity, provided saliva samples each morning, and completed an ADHD symptom checklist 
every evening for 35 days. Results indicated decreased levels of E2 in the context of increased 
levels of either P4 or T was associated with higher ADHD symptoms on the following day, 
particularly for those with high trait impulsivity. Phase analyses suggested both an early follicular 
and early luteal, or post-ovulatory, increase in ADHD symptoms. Therefore, ADHD symptoms 
may change across the menstrual cycle in response to endogenous steroid changes.
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1. Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and impairing childhood 
neurodevelopmental disorder (APA, 2013; Bernfort et al., 2008; Pelham et al., 2007, 
Polanczyk et al., 2007; Sayal et al. 2017; Thomas et al., 2015) that often persists into 
adolescence and adulthood with a prevalence of approximately 3% in adults (Faraone & 
Biederman, 2005; Fayyad et al., 2017; Kessler et al., 2006; Wilcutt, 2012). ADHD is a 
heterogeneous condition, currently conceptualized theoretically using multiple pathway 
models (Nigg et al., 2004; Sonuga-Barke, 2005) and most accurately described using two 
continuous symptom dimensions of inattention and hyperactivity-impulsivity (Haslam et al., 
2006; Larsson et al., 2012; Marcus & Barry, 2011). Although ADHD is more frequently 
diagnosed in males, females with ADHD often become particularly impaired and exhibit 
comorbid disorders beginning during adolescence (Biederman et al., 1999; Hinshaw et al., 
2012; Hosain, et al., 2012; Lahey et al. 1994; Quinn, 2005; Robison et al., 2008). The 
mechanisms of such sex differences remain unclear yet fundamental to understanding 
ADHD and sex differences in ADHD.
Prior work suggests a role for organizational testosterone (T) in ADHD symptoms in both 
sexes (Wang et al., 2017), but particularly males (Martel, 2009; McFadden et al., 2005). 
Women and girls are under-studied and in particular, activational hormonal effects remain 
essentially unstudied in ADHD. Case studies have suggested that ADHD symptoms may 
worsen the week before menstruation (during declining estrogen and progesterone; Quinn, 
2005) and improve during pregnancy (during elevated estrogen and progesterone (Nadeau & 
Quinn, 2002), but empirical work is lacking.
Higher estradiol (E2) and progesterone (P4) have been generally linked to enhanced 
executive function (EF) and attention (e.g., Hatta & Nagaya, 2009), which appear to improve 
during cycle phases characterized by elevated E2 and P4 (Gogos, 2013; Howard et al., 1988; 
Jacobs & D’Esposito, 2011; Lord & Taylor, 1991; Rosenberg & Park, 2002; Segal, 2012; 
Vranic´ & Hromatko, 2008; Solís-Ortiz & Corsi-Cabrera, 2008; Solis-Ortiz et al., 2004). 
Further, verbal fluency, verbal learning and memory appear to improve with administration 
of T in women (Davison et al., 2011; Drake et al., 2000), whereas response inhibition 
performance decreases (Bjork et al., 2001). Given that weak EF is a prominent correlate and 
possible marker of ADHD, this prior work suggests a potential role for cycling reproductive 
steroids in daily ADHD symptom expression.
During adulthood, impulsivity appears to be a particularly prominent marker of ADHD that 
is underpinned by cyclical steroid effects (Barkley et al., 2010). Studies of adult ADHD 
suggest robust associations with components of impulsivity (Lynam et al., 2006), including 
Negative Urgency (negative affect-driven rash action), Lack of Perseverance (inability to 
persist on a task through completion), and Lack of Planning (action without careful thinking; 
Miller et al., 2010; Pedersen et al., 2016; reviewed by Berg et al., 2015) with Negative 
Urgency potentially related to fluctuations in E2 and P4 through its links with affect 
(Eisenlohr-Moul et al., 2015). Sensation-Seeking (tendency to seek adventure) may be more 
specifically associated with hyperactivity-impulsivity (Lopez et al., 2015), as well as related 
to higher T (Campbell et al., 2010; Daitzman & Zuckerman, 1980; Roberti, 2004). Overall, 
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trait impulsivity appears prominently associated with both adult ADHD symptoms and 
steroid effects. Therefore, in line with rodent research (Löfgren et al., 2009), impulsivity 
may be a marker or a route to adult ADHD that is particularly sensitive to steroid effects. 
Thus, the possibility that steroid effects on ADHD may be apparent particularly for women 
with high trait impulsivity (particularly Negative Urgency and Sensation-Seeking) was 
examined herein.
1.1 Goals of the Present Study
The present study was conducted with the intention of examining the within-person 
covariations of reproductive steroids, including E2, P4, and T, with daily ADHD symptoms 
across the menstrual cycle. Based on prior work on E2 associations with EF, it was 
hypothesized that 1) between-women, lower average E2 across the entire menstrual cycle 
would be associated with higher ADHD symptoms, 2) within-person declines in E2 (i.e., 
lower-than-average E2 for a given woman) would be associated with increases in ADHD 
symptoms, and that 3) within-person declines in E2 would be more strongly associated with 
increased ADHD symptoms, particularly for those with higher levels of trait impulsivity. 
Additionally, given the evidence for interactive effects of E2 and P4 in other externalizing 
psychopathologies (Eisenlohr-Moul et al., 2015; Klump et al., 2008; 2013). P4 was included 
as an exploratory moderating variable given established antagonistic effects on E2, and T 
was also included as an exploratory moderating variable due to associations of T with 
ADHD symptoms (Martel, 2009; McFadden et al., 2005) and sensation seeking (Campbell 
et al., 2010; Daitzman & Zuckerman, 1980; Roberti, 2004). Finally, 4) cycle phase effects 
were examined to more easily compare results to previous studies and to evaluate whether 
ADHD risk may be heightened during particular parts of the menstrual cycle exhibiting 
characteristic hormone profiles, such as the early luteal phase and the perimenstrual 
timeframe (see Appendix 1).
2. Methods and Materials
2.1 Participants
Participants were 32 naturally-cycling young females between the ages of 18 and 22 (M = 
19.43, SD = 1.38) recruited from the local university and surrounding community. The 
participants’ ethnic background broadly matched that of the community: 70.6% Caucasian, 
17.6% African American, and 11.8% other ethnic minority. Exclusionary criteria included 
primary sensorimotor handicap, neurological disorder, pervasive developmental disorder or 
intellectual disability, history of psychosis, current gynecological or thyroid disorders, 
irregular cycles (<21 days or >35 days), and current medical use of hormones, 
psychostimulants, or antipsychotic medications. 3 women reported prescribed SSRIs. Height 
and weight were measured since body mass index impacts reproductive steroids (Lukanova 
et al., 2004; BMI Mean = 24.37, SD = 6.33). Participants who completed any data collection 
received $50, those who completed >50% of participation received $75, and those who 
completed 100% of data collection received $100.
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2.2 Procedure
At an initial laboratory visit, participants provided informed consent via IRB-approved 
procedures and completed measure of study eligibility and trait measures of impulsivity. 
Eligible women then completed 35 days of morning saliva collection and evening online 
symptom reports, after which participants returned frozen samples to the laboratory. The 
number of measures administered was kept to a minimum to reduce participant burden 
during the lengthy data collection period. E2, P4, and T were assayed every other day, 
resulting in an average of 17 days of data (steroids and symptoms) per woman.
2.3 Measures
2.3.1. Trait Impulsivity—The UPPS-P Trait Impulsivity Scale, a 59-item questionnaire, 
assesses five components of trait impulsivity: Positive Urgency (positive affect-driven rash 
action), Negative Urgency (negative affect-driven rash action), Lack of Premeditation (action 
without careful thinking), Lack of Perseverance (inability to remain with a task through 
completion), and Sensation Seeking (tendency to seek adventure; Whiteside & Lynam, 
2001) The scales demonstrate excellent reliability and validity (Lynam et al., 2006; Cyders 
et al., 2007). In the current sample, Lack of Perseverance exhibited fair reliability (α = .56) 
and Lack of Premeditation, Negative Urgency, Positive Urgency and Sensation Seeking 
exhibited good reliability (α = .82–.93).
2.3.2. Daily ADHD Symptoms—Daily symptoms were measured using the Current 
ADHD Symptoms Scale (CSS): Self-report, a symptom checklist for ADHD symptoms and 
impairment (Barkley & Murphy, 2006). Participants were instructed to rate their symptoms 
for the day every day in the evening. Symptom counts were used for analysis rather than 
diagnosis, as the sample was community-recruited, and ADHD appears best characterized as 
a continuum of symptoms (Haslam et al., 2006; Marcus & Barry, 2011). Total Hyperactive-
Impulsive symptoms ranged from 0 to 9 (M = .32, SD = .66; α = .66), and total Inattentive 
symptoms ranged from 0 to 9 (M = .20, SD = .65; α = .72). Log transformations were 
applied and resulted in normally distributed residuals in all analyses.
2.3.3 Reproductive Steroids: 17β-Estradiol (E2), Progesterone (P4), and 
Testosterone (T)—Saliva samples were collected via passive drool by participants in the 
morning thirty minutes after waking and were subsequently frozen. Participants were 
instructed not to eat, drink, brush teeth, or smoke before saliva collection. No participant 
reported violation of this morning protocol in daily diaries. Samples from every other day 
were analyzed. Serum E2 (pg/mL), P4 (pg/mL), and T (pg/mL) were determined using 
enzyme immunoassay kits available through Salimetrics. For E2, the Salimetrics 17β-
Estradiol immunoassay kit had a sensitivity of 0.1 pg/mL and high precision (% coefficient 
of variation ranging from .7 to 14.5). For P4, the Salimetrics immunoassay kits had a 
sensitivity of 5 pg/mL (from 0) and a precision of percent coefficient of variation between 
1.05 and 14.8. For T, the Salimetrics immunoassay kits had a sensitivity of 1pg/dL and 
precision of percent coefficient of variation between 1.2 and 18.9 All participants showed 
peak P4 levels consistent with an ovulatory cycle (Howards et al., 2009). Finally, steroids 
generally showed expected trajectories across the menstrual cycle: E2 demonstrated a 
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midcycle peak and secondary peak during the midluteal phase, P4 was low during the 
follicular phase and peaked during the luteal phase, and T showed a small mid-cycle peak.
The following predictors were defined for E2, P4, and T: (1) steroid averages across all 
observations within a participant, representing between-person differences in total exposure 
across the cycle, (2) steroid standard deviation across all observations within a participant, 
representing between-person differences in within-person variance across the cycle, and (3) 
recent steroid levels relative to one’s own average and standard deviation across all 
observations (within-person levels; Klump et al., 2008)1, defined as yesterday’s value minus 
the person average, divided by the person standard deviation. The one-day lag for the impact 
on ADHD symptoms was chosen to correspond to the 24 hour lag for ovarian steroid effects 
on behavior in animals (Bless, McGinnis, Mitchell, Hartwell, & Mitchell, 1997).
2.3.4. Cycle Phase Coding—Menstrual cycle phase was coded as described by Edler, 
Lipson, & Keel (2006). We then created an additional phase variable to differentiate pre- and 
post-ovulatory phases. To do this, we identified four pre-E2-peak and four post-E2 peak 
days; after identifying the ovulatory E2 peak, the day of the ovulatory E2 peak and the three 
days prior comprised the “pre-ovulatory” phase, while the four days after the ovulatory peak 
comprised the “post-ovulatory” phase. Five total phases were coded, with no overlap: 
Follicular, Preovulatory, Postovulatory, Midluteal, and Premenstrual.
2.4. Statistical Analysis
First, steroid means and standard deviations were correlated with impulsivity and average 
symptoms using spearman rank correlations (due to skewed distributions) partialling age and 
BMI. Next, linear mixed-effect models examined cycle phase and within-person steroid 
variation as predictors. In steroid models, we predicted today’s symptoms from BMI, 
yesterday’s person-standardized E2, P4, and T, and the two-way interactions between all 
steroids. Trait impulsivity variables were considered as moderators. Random slopes were 
specified for within-person predictors, and an additional term specified an autoregressive 
covariance structure (day – 1). Coefficients and odds ratios for within-person hormonal 
effects can be interpreted as the effect of a one person-SD increase in the predictor above 
one’s mean. Visual inspection of distributions and residuals indicated that assumptions of 
normality and homoscedasticity were met. In order to evaluate their robustness, moderation 
analyses were also carried out excluding the highest and lowest 10% of observations on the 
moderator. Using the Intraclass Correlations (ICCs) for each outcome and equations 
provided by Snijders and Bosker (1999), calculations indicated 80% power to detect 
conventionally small-to-medium effects (Klump et al., 2013; smallest detectible effects for 
cross-level interaction were f2 = .085 – .091).
3. Results
ICCs revealed that the majority of variance in symptoms was at the within-person level for 
Inattentive Symptoms (15% stable between-person variance; ICC = .15, NMI = .18, NMISE 
1Values on this variable are centered around one’s personal average for that steroid; therefore, negative values indicate lower-than-
average recent levels, and positive values indicate higher-than-average recent levels.
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= .048) and Hyperactive/Impulsive symptoms (10% stable between-person variance; ICC = .
10, NMI = .13, NMISE = .031). Therefore, ADHD symptoms were more state-like than 
trait-like, and analyses focused on within-person variance in symptoms were therefore most 
relevant to explaining symptom variance.
1) Association between Average Hormone Levels and ADHD Symptoms
Table 1 presents correlations of steroid means and variances with risk variables. Higher 
average E2 predicted less inattention, and greater E2 variance was associated with lower 
Negative Urgency. Higher average P4 correlated with lower inattention, Positive Urgency, 
Sensation Seeking, and Lack of Premeditation, and greater P4 variance predicted lower 
Negative Urgency, Positive Urgency, Sensation Seeking, and inattention. Greater variance in 
T predicted higher Positive Urgency and Sensation Seeking.
2) Do Higher or Lower Recent Steroid Levels Impact ADHD Symptoms?
Results of models predicting daily ADHD symptoms from recent steroids and their 
interactions revealed no significant associations (see Table 2). However, the existence of 
random effects of E2, P4, and T indicated that the impact of steroids varied as a function of 
between-person factors.
3) Do Impulsivity Traits Moderate the Impact of Daily Steroids on ADHD Symptoms?
Table 2 provides results of moderator analysis of the UPPS-P subscales on steroid-symptom 
links. All five UPPS-P subscales moderated at least one steroid-symptom association. 
However, sensitivity analyses revealed that moderation of steroid effects by Lack of 
Premeditation and Lack of Perseverance were not robust to elimination of extreme 
observations. Therefore, we report and discuss only the more robust moderating effects of 
Negative Urgency, Positive Urgency, and Sensation Seeking.
3a) Moderated Interactive Effects of E2 and P4—Only among women high in 
Negative Urgency, Positive Urgency, and Sensation Seeking (+1 SD), there were significant 
interactive effects of E2 and P4 on both inattention and hyperactivity (Figures 1, 2, and 3). 
These interactions took a similar form in each case: in the context of higher-than-average P4 
(the luteal phase), lower-than-average E2 predicted higher symptoms.
3b) Moderated Effects of T and E2 X T—Among women high in Sensation Seeking 
(+1 SD), higher-than-average T predicted increased hyperactivity/impulsivity; among 
women low in Sensation Seeking (−1 SD), higher-than-average T predicted decreased 
hyperactivity/impulsivity. Only among women high in Sensation Seeking, E2 and T 
interacted to predict inattention; when T was higher than usual, higher E2 predicted lower 
symptoms of inattention; when T was lower than usual, higher E2 predicted higher 
symptoms of inattention.
In Figure 3, we provide means plots to illustrate the interactive effects of E2 with both P4 
and T in predicting inattention across the cycle; smoothed levels of hormones and symptoms 
are plotted across the cycle among the top 33% of sensation seeking scorers. In Figure 4, we 
similarly illustrate the impact of T on hyperactivity/impulsivity across the cycle.
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4) Does Cycle Phase Impact ADHD Symptoms?
Next, we examined the influence of cycle phase on daily symptoms (see Appendix 1). 
Within-person analysis revealed no significant differences between phases for hyperactivity/
impulsivity, but the postovulatory phase was characterized by higher inattentive symptoms 
than all other phases (all p’s < .01).
4a) Do Impulsive Traits Alter the Impact of Cycle Phase on ADHD Symptoms?
—We then examined the moderating influence of UPPS-P impulsivity variables on within-
person associations of cycle phase with daily symptoms. Only in women high (+1 SD) in 
Positive Urgency or Sensation Seeking, the follicular and postovulatory phases were 
characterized by greater hyperactivity/impulsivity than the midluteal, premenstrual, and 
preovulatory phases (all p’s < .05). Only in women high on Sensation Seeking, Positive 
Urgency, and Lack of Premeditation (+1 SD), the follicular and postovulatory phases were 
each characterized by greater inattentive symptoms relative to all other phases (all p’s < .05). 
Only for women high in Positive Urgency (+1 SD), symptoms in the postovulatory phase 
were higher than the follicular phase (p < .05).
4. Discussion
In the first study to examine daily reproductive hormone levels with subsequent daily ADHD 
symptom expression, lower-than-average E2 in the context of higher-than-average P4 or T 
predicted next day increase in ADHD symptoms. The effect was magnified by high baseline 
trait impulsivity, suggesting that high trait impulsivity may be a route to ADHD symptoms 
in young adult women that is particularly sensitive to steroid influence. The within-person 
effects of decreased E2 during elevated P4 or T were complimented by our cycle phase 
findings, which suggested postovulatory and follicular elevations in symptoms among 
vulnerable women. Between-person associations of average E2 and P4 with average ADHD 
symptoms further indicated that low (and low variance in) E2 and P4 predicted greater 
symptoms. In addition, greater variation in T was linked with increased ADHD symptoms, 
whereas average levels were not.
Associations between low E2 and increased ADHD symptoms are in line with evidence that 
decreased E2 reduces EF (Jacobs et al., 1998; Schmidt et al., 1996; Sherwin, 1997), perhaps 
particularly among women with genotypic risk for low prefrontal dopamine and elevated 
trait impulsivity (Jacobs & D’Esposito, 2011). E2 effects on dopaminergic striatal circuits by 
reducing dopamine receptors and increasing dopamine release may therefore mediate these 
effects (Archer, 1999; Gibbs, 2010), particularly in the prefrontal cortex (Berman et al., 
1997).
Our work replicates antagonistic effects of E2 and P4 in externalizing disorders (Eisenlohr-
Moul et al., 2015; Klump et al., 2008; 2013; Singh, Su, & Ng, 2013) and is the first to 
indicate an antagonistic relationship of E2 and T. Notably, although our interactive steroid 
findings (high P4, low E2) might be initially seen as suggestive of a premenstrual 
exacerbation such as those described in case studies (Quinn, 2005), moderated cycle phase 
findings instead suggest strong postovulatory (rather than premenstrual) worsening of 
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symptoms with a secondary early follicular peak. To our knowledge, this is also the first 
study to identify post-ovulatory risk for ADHD symptoms.
Notably, these effects of low E2 on ADHD symptoms were only present during periods of 
high P4 and T. P4 and T may work in slightly different ways to increase the salience of 
environmental cues that may facilitate distractibility and risk taking; elevated or increasing 
P4 heightens attention to social cues relevant to social affiliation in women (Maner & Miller, 
2014), while elevated or increasing T facilitates attention to social dominance opportunities 
(Albert et al., 1993; Eisenegger et al., 2011; Mazur & Booth, 1998). It is possible, then, that 
heightened levels of either P4 or T set the stage for vulnerability to (social) environmental 
distractions and opportunities for impulsive behavior, and concurrent drops in E2, with their 
associated reductions in EF, further increase risk for symptoms. This could function to 
increase the probability of indiscriminate mating and conception due to increases in 
impulsive behavior just post-ovulation.
Although this study was the first to directly examine steroids and ADHD symptoms, it is not 
without limitations. A one-day lag was assumed for the impact of hormones on ADHD 
symptoms based on a study of rats (Bless et al., 1997). An important area of future work is 
verifying the time period of effects in humans. In addition, use of a nonclinical sample may 
limit generalizability of these findings, despite a consensus that ADHD is best 
conceptualized dimensionally (Barkley, 2006; Haslam et al., 2006; Larsson et al., 2012; 
Marcus & Barry, 2011). Further, the present study had limited diagnostic information (i.e., 
one measure of ADHD) due to practical constraints and also did not explore clinical 
comorbidities (e.g., Borderline Personality Disorder; DeSoto et al., 2003; Eisenlohr-Moul et 
al., 2015), which might have impacted study findings. Future studies should utilize multiple 
measures of ADHD symptoms, use or develop a measure designed to measure daily changes 
in symptoms, and explore or control for potential comorbidities. The present study also 
relied on self-report. Future studies should utilize other-report and/or neuropsychological 
testing. Finally, analyses utilized data collected every other day (vs. every day) due to 
expense of assays; more fine-grained analysis is an important extension of current results. 
Finally, rodent models suggest that progesterone injection in intact rats leads to hypoactivity 
(Rodier 1971), and administration of estradiol reverses hypoactivity in ovariectomized rats 
(Gorzek et al., 2007), effects that appear to be in the opposite direction of the present study’s 
findings. Additional comparative work will be important, although -- in this case -- it might 
be argued that the study of naturally-occurring cyclic variations in hormones may lead to a 
very different pattern of results compared to more rigorous examination of 
ovariectomization and substitution effects on behavior.
5. Conclusions
Results demonstrating steroid effects across the menstrual cycle on ADHD symptoms for 
vulnerable women suggests the possibility that ADHD symptoms may be more state-like 
and variable within women than previously thought. If results that ADHD symptoms vary 
across the menstrual cycle in tandem with steroid changes are replicated, this may suggest 
the need for clinicians to ask for information about cycle phase, hormonal profiles, use of 
hormonal birth control, and/or stage of life (i.e., pre- or post-puberty) during ADHD 
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assessment in women. These results also suggest the possibility that EF and psychostimulant 
response might vary across the cycle. These represent critical directions for future work.
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Highlights
• ADHD symptoms are higher when estradiol decreases
• Low estradiol risky for ADHD in context of high progesterone or testosterone
• Associations are stronger for highly impulsive women
• ADHD symptoms increased during early follicular and early luteal phases
• ADHD symptoms change across menstrual cycle in young adult women
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Figure 1. 
Moderating Influence of Sensation Seeking on (A) the Effect of Testosterone and (B) the 
Interactive Effect of Estradiol and Testosterone on Daily ADHD Symptoms
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Figure 2. 
Moderating Influence of Negative Urgency (A), Positive Urgency (B), and Sensation 
Seeking (C) on the Interactive Effect of E2 and P4 on Daily Hyperactive/Impulsive ADHD 
Symptoms.
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Figure 3. 
Moderating Influence of Negative Urgency (A), Positive Urgency (B), and Sensation 
Seeking (C) on the Interactive Effect of E2 and P4 on Daily Inattentive ADHD Symptoms
Roberts et al. Page 16
Psychoneuroendocrinology. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Means plots illustrating the interactive effects of estradiol with testosterone and progesterone 
in predicting inattentive symptoms across the menstrual cycle among women high (A) and 
low (B) in sensation seeking.
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Figure 5. 
Smoothed means plots illustrating the effects of testosterone among women high in 
sensation seeking (A) and the interactive effects of estradiol with progesterone in predicting 
hyperactive/impulsive symptoms across the menstrual cycle among women high in negative 
urgency (B).
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Table 2
Models Predicting Daily ADHD Symptoms Person-Standardized Recent Ovarian Steroid Levels
Daily Outcome
Parameter
Hyperactive/Impulsive
Symptoms
Inattentive
Symptoms
Estimate SE Estimate SE
Intercept 0.13 0.03 0.16 0.05
BMI 0.04 0.03 0.04 0.05
E2 −0.02 0.02 0.00 0.02
P4 0.02 0.02 −0.01 0.02
T 0.00 0.02 0.02 0.02
E2 × P4 −0.01 0.02 0.00 0.02
E2 × T −0.02 0.01 −0.01 0.02
P4 × T 0.01 0.02 0.00 0.02
Models Predicting Daily ADHD Symptoms from the Interaction of Negative Urgency and Recent
Ovarian Steroid Levels
Daily Outcome
Parameter
Hyperactive/Impulsive
Symptoms
Inattentive
Symptoms
Estimate SE Estimate SE
Intercept 0.12 0.03 0.17 0.04
BMI 0.00 0.03 −0.01 0.04
E2 −0.02 0.01 −0.01 0.02
P4 0.04** 0.01 0.00 0.02
T −0.01 0.01 0.00 0.02
E2 × P4
−0.03* 0.01 −0.05** 0.02
E2 × T 0.00 0.01 −0.01 0.02
P4 × T 0.00 0.01 0.04 0.03
Negative Urgency (NU) 0.10** 0.03 0.14** 0.05
NU × E2
−0.03* 0.02 −0.01 0.02
NU × P4 0.05** 0.02 0.00 0.02
NU × T 0.01 0.01 0.02 0.02
NU × E2 × P4
−0.04* 0.01 −0.05* 0.02
NU × E2 × T 0.01 0.01 0.01 0.02
NU × P4 × 0.00 0.02 0.01 0.02
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Models Predicting Daily ADHD Symptoms from the Interaction of Positive Urgency and Recent
Ovarian Steroid Levels
Daily Outcome
Parameter
Hyperactive/Impulsive
Symptoms
Inattentive
Symptoms
Estimate SE Estimate SE
Intercept 0.13 0.03 0.18 0.04
BMI 0.02 0.03 −0.02 0.04
E2 −0.02 0.02 0.01 0.02
P4 0.02 0.02 −0.01 0.02
T −0.00 0.02 0.00 0.02
E2 × P4 −0.01 0.02
−0.05** 0.02
E2 × T −0.02 0.01 −0.02 0.02
P4 × T 0.01 0.02 0.03 0.02
Positive Urgency (PU) 0.08** 0.03 0.17*** 0.04
PU × E2
−0.04* 0.02 0.01 0.02
PU × P4 0.03* 0.02 0.00 0.02
PU × T 0.01 0.02 0.00 0.02
PU × E2 × P4
−0.03* 0.01 −0.04* 0.02
PU × E2 × 0.01 0.02 −0.02 0.02
PU × P4 × 0.02 0.02 0.00 0.02
Models Predicting Daily ADHD Symptoms from the Interaction of Sensation Seeking and
Recent Ovarian Steroid Levels
Daily Outcome
Parameter
Hyperactive/Impulsive
Symptoms
Inattentive
Symptoms
Estimate SE Estimate SE
Intercept 0.13 0.03 0.17 0.04
BMI 0.04 0.03 0.04 0.04
E2 −0.01 0.01 0.01 0.02
P4 0.03* 0.02 −0.01 0.02
T −0.01 0.01 0.02 0.02
E2 × P4
−0.03* 0.01 −0.05* 0.02
E2 × T 0.00 0.01 −0.01 0.02
P4 × T 0.01 0.01 0.03 0.02
Sensation Seeking (SS) 0.09* 0.03 0.13 0.04
SS × E2 −0.01 0.02 −0.02 0.02
SS × P4 0.03 0.02 0.00 0.02
SS × T 0.03* 0.01 0.02 0.02
SS × E2 × P4
−0.03** 0.01 −0.04* 0.02
SS × E2 × 0.00 0.01
−0.04* 0.02
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Models Predicting Daily ADHD Symptoms from the Interaction of Sensation Seeking and
Recent Ovarian Steroid Levels
Daily Outcome
Parameter
Hyperactive/Impulsive
Symptoms
Inattentive
Symptoms
Estimate SE Estimate SE
SS × P4 × 0.02 0.02 0.01 0.02
Note.
*p < .05,
**p < .01,
***p < .001.
E2 = Estradiol, P4 = Progesterone. T = Testosterone.
Significant fixed effects are shown in bold.
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